A
Amira Pharmaceuticals
Small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat
About Amira Pharmaceuticals
Amira Pharmaceuticals, established in 2005 in San Diego, CA, operated as a small-molecule pharmaceutical company concentrating on the discovery and initial development of novel drugs for inflammatory and fibrotic diseases. The scientific founding team, which included Peppi Prasit, Jilly Evans, and John Hutchinson, were veterans of Merck. Their collective experience was instrumental in the discovery of multiple drugs, including the well-known anti-inflammatory medication Singulair®. This team of seasoned 'drug hunters' formed Amira with minimal initial intellectual property, aiming to replicate their past successes by identifying new disease pathways and developing high-value compounds.
The company's business model focused on combining the rigorous, effective decision-making of a large pharmaceutical firm with the agile and energetic environment of a small startup. This approach enabled the efficient development of novel compounds. Amira's primary activities involved preclinical and early-phase clinical research into bioactive lipid pathways and complex signaling processes that control conditions like asthma, cardiovascular disease, and fibrosis. A key partnership was established with GlaxoSmithKline to co-develop FLAP (5-lipoxygenase activating protein) inhibitors for respiratory and cardiovascular diseases.
A significant milestone for Amira was the development of its fibrosis program, headlined by the lead asset AM152. This orally available LPA1 receptor antagonist was developed for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (scleroderma). By 2011, AM152 had successfully completed Phase I clinical trials and was prepared for Phase IIa studies. The company also developed a preclinical autotaxin program with potential applications in treating neuropathic pain and cancer metastases. In September 2011, Amira Pharmaceuticals was acquired by Bristol-Myers Squibb, becoming a wholly-owned subsidiary. The transaction involved an upfront cash payment of $325 million, with an additional $150 million in potential milestone payments, marking a significant validation of Amira's drug discovery platform and pipeline.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2005
- Headquarters
- San Diego, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 41.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2011 | $475M | $475M | Bristol-Myers Squibb | — |
| SERIES B✓Equity / VC | Mar 2007 | $25M | $100M | Prospect Venture Partners · Novo Holdings · Versant Ventures · Avalon Ventures | — |
Growth signals
Latest recorded traffic for Amira Pharmaceuticals is 90 monthly website visits. Amira Pharmaceuticals's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Amira Pharmaceuticals in the San Diego ecosystem
The Amira Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Avalon Ventures- PPProspect Venture Partners
Versant Ventures
Novo Seeds
Novo Holdings
Other known investors1 additional known investor
Bristol-Myers Squibb
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amira Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amira Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









